Effect of Prolonged Methylprednisolone Therapy in Unresolving Acute Respiratory Distress Syndrome
Article Abstract:
Prolonged treatment with methylprednisolone may be beneficial in patients with acute respiratory distress syndrome (ARDS). Mortality rates in ARDS patients often exceed 50%. Researchers assigned 16 ARDS patients to receive methylprednisolone treatment for 32 days and 8 ARDS patients to receive a placebo. Methylprednisolone improved lung function and reduced the risk of multiple organ failure. Mortality rates during hospitalization were 62% in the placebo group and 12% in the methylprednisolone group.
Publication Name: JAMA, The Journal of the American Medical Association
Subject: Health
ISSN: 0098-7484
Year: 1998
User Contributions:
Comment about this article or add new information about this topic:
Effect of Prolonged Methylprednisolone Therapy in Unresolving Acute Respiratory Distress Syndrome
Article Abstract:
Prolonged treatment with methylprednisolone may be beneficial in patients with acute respiratory distress syndrome (ARDS). Mortality rates in ARDS patients often exceed 50%. Researchers assigned 16 ARDS patients to receive methylprednisolone treatment for 32 days and 8 ARDS patients to receive a placebo. Methylprednisolone improved lung function and reduced the risk of multiple organ failure. Mortality rates during hospitalization were 62% in the placebo group and 12% in the methylprednisolone group.
Publication Name: JAMA, The Journal of the American Medical Association
Subject: Health
ISSN: 0098-7484
Year: 1998
User Contributions:
Comment about this article or add new information about this topic:
Effect of Prolonged Methylprednisolone Therapy in Unresolving Acute Respiratory Distress Syndrome
Article Abstract:
Prolonged treatment with methylprednisolone may be beneficial in patients with acute respiratory distress syndrome (ARDS). Mortality rates in ARDS patients often exceed 50%. Researchers assigned 16 ARDS patients to receive methylprednisolone treatment for 32 days and 8 ARDS patients to receive a placebo. Methylprednisolone improved lung function and reduced the risk of multiple organ failure. Mortality rates during hospitalization were 62% in the placebo group and 12% in the methylprednisolone group.
Publication Name: JAMA, The Journal of the American Medical Association
Subject: Health
ISSN: 0098-7484
Year: 1998
User Contributions:
Comment about this article or add new information about this topic:
- Abstracts: Aerosolized surfactant in adults with sepsis-induced acute respiratory distress syndrome. Effects of aerosolized surfactant in patients with stable chronic bronchitis: a prospective randomized controlled trial
- Abstracts: Effectiveness of computer-generated telephone messages in increasing clinic visits. Impact of measurement and feedback on vaccination coverage in public clinics, 1988-1994
- Abstracts: Effect of Excessive Weight Gain With Intensive Therapy of Type 1 Diabetes on Lipid Levels and Blood Pressure
- Abstracts: Effect of Excessive Weight Gain With Intensive Therapy of Type 1 Diabetes on Lipid Levels and Blood Pressure. part 2
- Abstracts: Nicotine Metabolism and Intake in Black and White Smokers